TD Cowen raises target for Twist Bioscience stock to USD 190

Published on 10/27/2026 at 14:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Twist Bioscience stock costs EUR 131.65 on October 27, 2026. Results are due November 12, 2026 after fiscal third-quarter revenue rose 23.2 percent.

Analysts and results set the frame

TD Cowen raised its target to USD 190 on October 13, 2026.
Fiscal third-quarter revenue reached USD 118.38 million, up 23.2 percent year over year.
Twist Bioscience stock trades at EUR 131.65 at 2:10 p.m. CET at Lang & Schwarz on October 27, 2026.
Fiscal fourth-quarter results are scheduled for November 12, 2026.

TWST, US90184D1000, Illustration mit AI erstellt.

Twist Bioscience (ISIN US90184D1000) was trading at EUR 131.65 at Lang & Schwarz on October 27, 2026, at 2:10 p.m. CET. The latest analyst catalyst came from TD Cowen, which raised its price target from USD 115 to USD 190 on October 13, 2026, according to Benzinga.

Analysts widen their target range

The TD Cowen move followed a sequence of higher targets. On October 1, 2026, Guggenheim lifted its target from USD 107 to USD 212, while Canaccord Genuity raised its target from USD 120 to USD 205 on October 12, 2026, according to Benzinga. The spread matters because the published targets range from a cautious view to materially higher levels.

What does the loss mean for valuation?

Twist Bioscience grew fiscal third-quarter revenue 23.2 percent year over year to USD 118.38 million, but diluted earnings per share were a loss of USD 0.56. The figures came with a consolidated net loss of USD 35.05 million for the quarter, according to MarketBeat. Revenue growth is therefore running ahead of profitability, leaving the earnings trajectory central to the valuation debate.

Three recent signals for investors

On October 1, 2026, Guggenheim set a USD 212 target. On October 12, 2026, Canaccord Genuity set a USD 205 target. On October 13, 2026, TD Cowen set a USD 190 target, according to Benzinga.

Results date is November 12

The next dated events are November 12, 2026, when Twist Bioscience will publish fiscal fourth-quarter and full-year 2026 results before the market opens and host its conference call at 8:00 a.m. ET, as Business Wire reported on October 26, 2026.

Stock price and upcoming results

The company operates in biotechnology and uses a silicon-chip platform to manufacture synthetic DNA products. Its market capitalization was USD 9.6 billion as of October 26, 2026, while the 52-week range was USD 23.30 to USD 219.71. Twist Bioscience was trading at EUR 131.65 at Lang & Schwarz on October 27, 2026, at 2:10 p.m. CET.

The further course of trading is shown by the continuously updated real-time quote of Twist Bioscience stock.